23-25 October 2024

Rockville, MD - USA

Bayes 2023

DAY 1 – 25th October

TIME
SPEAKER
AFFILIATION
08:30 - 09:00
Registration
09:00 - 12:30
Thomas Jaki, Pavel Mozgunov
University of Cambridge
SHORT COURSE:
Basket trials – a powerful tool for precision medicine trials
12:30 - 13:30
Lunch
13:30 - 13:45
Welcome and Opening
13:45 - 14:15
Kit Roes
Radboud University Nijmegen Medical Centre
Exploring regulatory perspectives on Bayesian statistics in assessment and decision making
14:15 - 14:35
Bradley P. Carlin
PharmaLex
Bayesian Adaptive Phase I-II designs for Evaluating Safety and Efficacy in Dual-Agent Oncological Drug Development
14:35 - 14:55
Jan Priel
Cytel
A confirmatory adaptive Phase II/III design with Bayesian decision rules for dose selection and sample size re-estimation – a case study
14:55 - 15:15
Leonhard Held
University of Zurich
A Bayesian Perspective on the Two-Trial Rule
15:15 - 15:40
Coffee break
15:40 - 16:10
François Beckers
Sanofi-Pasteur
Application of Bayesian approaches in drug development: starting a virtuous cycle
16:10 - 16:30
Lauren J. Frazee
PharmaLex
Issues in Regulatory Acceptability of Bayesian Historical Data Borrowing Methods
16:30 - 16:50
Peter van de Ven
University Medical Center Utrecht
A new Bayesian adaptive decision-theoretic design for multi-arm multi-stage clinical trials illustrated by an application in exercise oncology

The BAYES Organising Committee is delighted to invite all registered attendees to the social dinner at Stadskasteel Oudaen

DAY 2 – 26th October

TIME
SPEAKER
AFFILIATION
PRESENTATION
08:30 - 09:00
Joost van Rosmalen
Erasmus MC
Augmenting treatment arms with external data through propensity-score weighted power-priors: an application in expanded access
09:00 - 09:20
Annette Kopp-Schneider
German Cancer Research Center
Operating characteristics of clinical trials with borrowing from external data: one-arm and hybrid control arm trials
09:20 - 09:40
Emma K Mackay
Cytel
A Novel Information Borrowing Approach for Evaluating Response in Pediatric Basket Trials with Limited Sample Sizes
09:40 - 10:00
Samuel Pawel
University of Zurich
Power Priors for Replication Studies
10:00 - 10:25 MY TALK IN 3 MINUTES
Tanzy Love
University of Rochester
Clustering historical controls for a continuous outcome in a Bayesian Phase II vulvodynia trial design
Giles Partington
Phastar
Bayesian Elicitation for rare diseases trials
Wilmar Igl
Icon
Hype, Not Hope: Using Bayesian Methods in Drug Development
Forrest Williamson
Eli Lilly & Company
A Bioethical Defense of Bayesian Methods in Drug Development
Tanja Krone
Netherlands Organization for Applied Scientific research (TNO)
Bayesian Network Models to combine and update models using incomplete data
10:25 - 10:50
Coffee break
10:50 - 11:20
Ethan Alt
University of North Carolina on Chapel Hill, USA
LEAP: The latent exchangeability prior for borrowing information from historical data
11:20 - 11:40
Silvia Calderazzo
German Cancer Research Center
Robust incorporation of external information in hypothesis testing
11:40 - 12:00
Anduena Rexhepi
Boehringer Ingelheim
Systematic Value Exploration of Propensity Score and Borrowing Approaches
12:00 - 12:20
František Bartoš
University of Amsterdam
Empirical prior distributions for Bayesian meta-analyses of binary and time to event outcomes
12:20 - 13:20
Lunch
13:20 - 13:50
Veera Baladandayuthapani
University of Michigan
Bayesian Models for Multi-omic Multi-system Integration
13:50 - 14:10
Hakem Ben Addi
GSK Vaccines
Longitudinal Analysis of In Vivo mRNA Expression Data Using Bayesian P-Splines
14:10 - 14:30
Yimer Wasihun Kifle
Janssen Pharmaceutical
Formulating two classes of power priors to leverage historical accelerated stability data
14:30 - 14:50
Francisca Galindo Garre
Janssen Pharmaceutical
Advantages of using the Bayesian Framework for Modelling the relationship between Volume, Freezing Rate, Supercooling and Aggregation in Vaccines
14:50 - 15:15
MY TALK IN 3 MINUTES
Tobias Eilert
Boehringer Ingelheim
A Modern Approach to Stability Studies via Bayesian Linear Mixed Models Incorporating Auxiliary Effects
Juho Timonen
Aalto University & Generable Inc.
Longitudinal Gaussian Process Modeling in Biostatistics
Lira Pi
PharmaLex
Bayesian inference model with nested effects to perform differential gene expression analysis from multi-level spatial transcriptomics data with multiple conditions
Clément Laloux
PharmaLex
Penalized Bayesian Methods for Product Ranking Using Both Positive and Negative References
15:15 - 15:40
Coffee break
15:40 - 16:10
Lisa Hampson
Novartis
Quantitative Decision Making for drug development: the role of Bayesian methods in evaluating and communicating risk
16:10 - 16:30
James Salsbury
University of Sheffield
Assurance methods for designing a survival trial with delayed treatment effects
16:30 - 16:50
Anaïs Andrillon
Saryga
Surv-CRM-12: A Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression
16:50 - 17:10
Rajat Mukherjee
Mukherjee-Consultants
Interim Decisions with Time-to-Event Endpoints under Non-proportionality of Hazards
17:10 - 17:30
Sandrine Micallef
Debiopharm International SA
U-DESPA: a Utility-based Bayesian approach for dosage optimization relying on Dose-Exposure- Safety/Pharmacodynamics/anti-tumor activity relationship modeling for oncology clinical trials

DAY 3 – 27th October

TIME
SPEAKER
AFFILIATION
PRESENTATION
08:30 - 09:00
Sarah Zohar
INSERM
Coping with Information Loss and the Use of Auxiliary Sources of Data: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions
09:00 - 09:20
Greg Papageorgiou
GSK Vaccines
Joint modeling for the prediction of exacerbation events in patients with COPD
09:20 - 09:40
Francois Mercier
Roche Innovation Center Basel
Democratizing Bayesian joint models in clinical drug development: From premise to daily practice in oncology
09:40 - 10:00
Georgios Kazantzidis
Roche
Non-linear Bayesian joint models to estimate direct and indirect treatment effects in oncology clinical trials
10:00 - 10:20
James Willard
McGill University
Bayesian Optimization for Dual Agent Dose-Finding Trials
10:20 - 10:45
Coffee break
10:45 - 11:15
J. Kyle Wathen
Cytel
In a Sea of Design Options – Using Visualization to Navigate A Variety of Options for a Platform Trial
11:15 - 11:35
Dario Zocholl
Charité Universitaetsmedizin Berlin
Estimating the similarity between adult and pediatric dose-toxicity curves to inform pediatric dose-finding.
11:35 - 11:55
Christian Stock
Boehringer Ingelheim
Partial extrapolation in pediatric drug development using robust meta-analytic predictive priors, tipping point analysis and expert elicitation
11:55 - 12:15
Lan Tran
PharmaLex
Using R-INLA in Bayesian Adaptive Designs
12:15 - 12:35
Eric-Jan Wagenmakers
University of Amsterdam
Interim Design Analysis Using Bayes Factor Forecasts

SPONSORED BY

Code of Conduct

The Adolphe Quetelet Society is an official region of the International Biometric Society (IBS). As such the society endorses the same objectives and Code of Conduct as its mother organization:

IBS Code of Conduct : The International Biometric Society (IBS) highly values professional and appropriate behavior at all times. This involves scientific and ethical integrity, as well as respectful conduct towards others regardless of gender, gender identity and expression, age, sexual orientation, disability, physical appearances, race, religion (or lack thereof) or beliefs.

Members of the IBS, as well as everyone employed on behalf of IBS or attending events organized by IBS, are expected to endorse this position and they agree to be considerate in speech and actions, to respect others, and to refrain from demeaning, discriminatory, or harassing behavior and speech, at all times.

Copyright © 2024 Bayes-Pharma